SYS-CON MEDIA Authors: Pat Romanski, Elizabeth White, Glenn Rossman, Cynthia Dunlop, Peter Silva

News Feed Item

Albany College of Pharmacy and Health Sciences Faculty Member Receives $353,400 Grant for Leukemia Research

COLCHESTER, VT -- (Marketwire) -- 01/28/13 -- Karen Glass, Ph.D., assistant professor in the Department of Pharmaceutical Sciences at Albany College of Pharmacy and Health Sciences' Vermont Campus, has been awarded a three-year research grant totaling $353,400 from the National Institutes of Health (NIH). Dr. Glass will seek to identify new ways to prevent and treat a type of leukemia called Acute Myeloid Leukemia (AML).

What is AML?
AML is a cancer of the blood and bone marrow. In AML patients, cells that would typically develop into white blood cells, important for the immune system, grow at an abnormal rate, thereby interfering with the production of normal blood cells.

Research Project
Substances such as proteins regularly bind to our DNA, and in so doing, cause genes to be expressed or repressed (these binding substances are called "transcription factors"). The resulting series of interactions contribute to a range of bodily processes, one of which is the development of blood cells, including bone marrow cells.

Genetic mutations, however, can cause these cellular processes to break down. In AML, there is a mutation known as chromosomal translocation, where a chromosome breaks and incorrectly re-fuses to another chromosome.

Factors including environmental toxins, benzene exposure, and drugs used for chemotherapy may cause AML-related translocations, but in many cases, scientists are still unclear on the specific triggers. There is also much to be learned as to which specific combinations of gene mutations lead to AML and other forms of disease.

With support from students at the College, Dr. Glass will be studying the factors that regulate gene activity in AML and explore if these factors can be manipulated to treat or possibly prevent disease.

Quote from Dr. Glass
"There is no single factor, but rather a series of events, which leads to a disease such as AML," said Dr. Glass. "If we can better understand the basic mechanisms controlling gene expression and how chromosomal translocations lead to AML and other cancers, then we will be able to diagnose and treat AML patients more effectively. We may also be able to apply this knowledge in the treatment of other cancers and diseases."

The project described above is supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R15GM104865. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Albany College of Pharmacy and Health Sciences
Founded in 1881, Albany College of Pharmacy and Health Sciences is a private, independent institution committed to graduating the best health care minds in the world. The College's Vermont Campus is located in Colchester and is home to the only pharmacy program in the state of Vermont. The school's main campus is located in Albany, New York. For more information, please visit www.acphs.edu.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2211826

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Gil Chorbajian
Director of Communications
Albany College of Pharmacy and Health Sciences
Work: 518-694-7394
Mobile: 518-542-5532
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an In...
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy architecture and infrastructure into account. Then the reality is that most enterprises are embarking on a hybrid cloud...
In her General Session at 15th Cloud Expo, Anne Plese, Senior Consultant, Cloud Product Marketing, at Verizon Enterprise, will focus on finding the right mix of renting vs. buying Oracle capacity to scale to meet business demands, and offer validated Oracle database TCO models for Oracle development and testing environments. Anne Plese is a marketing and technology enthusiast/realist with over 19...
StackIQ offers a comprehensive software suite that automates the deployment, provisioning, and management of Big Infrastructure. With StackIQ’s software, you can spin up fully configured big data clusters, quickly and consistently — from bare-metal up to the applications layer — and manage them efficiently. Our software’s modular architecture allows customers to integrate nearly any application wi...
As Platform as a Service (PaaS) matures as a category, developers should have the ability to use the programming language of their choice to build applications and have access to a wide array of services. Bluemix is IBM's open cloud development platform that enables users to easily build cloud-based, creative mobile and web applications without having to spend large amounts of time and resources o...
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at Internet of @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, will discuss how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will nee...
When you set off to build an app that will change the world, designing your system architecture to be reliable and scalable is important but the stark reality is that, for your MVP, you probably had a “need for speed” (of development). You didn’t know what all the axes were to scale your application, where your stress points would be, and what weird and wonderful ways your customers would use it d...
Compute virtualization has been transformational, yet security policy implementation and enforcement has lagged behind in agility and automation. There are a number of key considerations when implementing policy in private and hybrid clouds. In his session at 15th Cloud Expo, Holland Barry, VP of Technology at Catbird, will discuss the impact of this new paradigm and what organizations can do to...
Samsung VP Jacopo Lenzi, who headed the company's recent SmartThings acquisition under the auspices of Samsung's Open Innovaction Center (OIC), answered a few questions we had about the deal. This interview was in conjunction with our interview with SmartThings CEO Alex Hawkinson. IoT Journal: SmartThings was developed in an open, standards-agnostic platform, and will now be part of Samsung's Ope...
SYS-CON Events announced today that Red Hat, the world's leading provider of open source solutions, will exhibit at Internet of @ThingsExpo, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Red Hat is the world's leading provider of open source software solutions, using a community-powered approach to reliable and high-performing cloud, Linux, ...